InflaRx reports Q3 EPS (EUR 0.30) vs. (EUR 0.13) last year

Reports Q3 revenue EUR 123,819 vs. EUR 60,803 last year. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx (IFRX), commented: “The start of the second half of 2024 has been a time of considerable momentum for the Company, and our leadership position in complement inhibition continues to strengthen. As we consider the remainder of the year, we remain well positioned to start our Phase 2a trial in two immuno-dermatology indications with INF904. We are excited about upcoming expected milestones looking into 2025, including the interim analysis of the vilobelimab Phase 3 trial in pyoderma gangrenosum and the first Phase 2a data readout from INF904.”